Zenobia Fragments — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Zenobia Fragments is a specialized provider of fragment screening libraries, operating as a division of Zenobia Therapeutics (founded 2008). The company leverages over two decades of expertise in fragment-based drug discovery to supply rigorously designed, pre-formatted compound collections that are pre-tested for solubility and ready for immediate screening. Its product lines, including 'Discovery' and 'Express' libraries, are used by research institutes worldwide to identify novel chemical starting points against challenging targets, including protein-protein interactions. The company is privately held, generates revenue from product sales, and is led by its founder and CSO, Dr. Vicki Nienaber, a key inventor of foundational FBLD technologies.

AntibodiesProteomics

Technology Platform

Design, curation, and pre-formatting of high-quality, solubility-tested chemical fragment libraries for fragment-based lead discovery (FBLD). Libraries are shipped as a dry film in pre-plated assay-ready wells.

Opportunities

Growth is tied to the expanding adoption of fragment-based drug discovery across academia and industry.

The company can leverage its strong reputation to upsell customers from its Express screening plates to its full Discovery libraries and resupply compounds.

There is also an opportunity to develop new, specialized fragment libraries for emerging modalities like targeted protein degradation.

Risk Factors

The company faces competition from larger life science suppliers offering fragment libraries.

Its focused business model is vulnerable to any decline in the popularity or funding of fragment-based screening approaches.

As a small team, scaling operations and sales reach may be challenging.

Competitive Landscape

Zenobia competes in the niche market of curated fragment libraries against larger diversified suppliers (e.g., MilliporeSigma, Charles River) and specialized chemistry providers. Its key differentiators are its founders' seminal reputation in FBLD, the pre-tested solubility and pre-plated 'dry film' format for convenience, and a focused collection proven against difficult targets like protein-protein interactions.

More companies in Small Molecule Drugs →More companies in United States →